Amgen AMG 133 launches weight loss Phase III clinical trial
On March 5th, the global clinical trial registry website clinicaltrials showed that Amgen has initiated two Phase III clinical trials (MARITIME-1 and MARITIME-2) for AMG 133 (Maridebart Cafraglutide, MariTide), marking the entry of AMG 133 into the Phase III development stage. AMG 133 is a first-in-class antibody-peptide conjugate developed by Amgen with an injection frequency of once every 4 weeks. It is composed of a fully human monoclonal antibody targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) conjugated to two GLP-1 analogs. It exerts its effects by inhibiting GIPR and activating the GLP-1 receptor (GLP-1R) to reduce food intake and regulate metabolism, thereby aiding in weight loss and lowering blood glucose levels. The hypoglycemic and weight loss effects of AMG 133 have been preliminarily validated in Phase II studies
According to the Zhitong Finance APP, on March 5th, the global clinical trial registration website clinicaltrials showed that Amgen (AMGN.US) has initiated two Phase III clinical trials (MARITIME-1 and MARITIME-2) for AMG 133 (Maridebart Cafraglutide, MariTide), marking the entry of AMG 133 into the Phase III development stage.
AMG 133 is a first-in-class antibody-peptide conjugate drug independently developed by Amgen, with an injection frequency of once every four weeks. It is composed of a fully human monoclonal antibody targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) conjugated to two GLP-1 analogs. It works by inhibiting GIPR and activating the GLP-1 receptor (GLP-1R) to reduce food intake and regulate metabolism, thereby aiding in weight loss and lowering blood sugar levels.
The blood sugar-lowering and weight loss effects of AMG 133 have been preliminarily validated in Phase II studies
